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Abstract 
 Adenosine is an endogenous nucleoside with pleiotropic effects in different 
physiological processes including circulation, renal blood flow, immune function, or 
glucose homeostasis. Changes in adenosine membrane transporters, adenosine receptors, 
and corresponding intracellular signalling network associate with development of 
pathologies of pregnancy, including preeclampsia. Preeclampsia is a cause of maternal and 
perinatal morbidity and mortality affecting 3-5% of pregnancies. Since the proposed 
mechanisms of preeclampsia development include adenosine-dependent biological effects, 
adenosine membrane transporters and receptors, and the associated signalling mechanisms 
might play a role in the pathophysiology of preeclampsia. Preeclampsia associates with 
increased adenosine concentration in the maternal blood and placental tissue, likely due to 
local hypoxia and ischemia (although not directly demonstrated), microthrombosis, 
increased catecholamine release, and platelet activation. In addition, abnormal expression 
and function of equilibrative nucleoside transporters is described in foetoplacental tissues 
from preeclampsia; however, the role of adenosine receptors in the aetiology of this disease 
is not well understood. Adenosine receptors activation may be related to abnormal 
trophoblast invasion, angiogenesis, and ischemia/reperfusion mechanisms in the placenta 
from preeclampsia. These mechanisms may explain only a low fraction of the associated 
abnormal transformation of spiral arteries in preeclampsia, triggering cellular stress and 
inflammatory mediators release from the placenta to the maternal circulation. Although 
increased adenosine concentration in preeclampsia may be a compensatory or adaptive 
mechanism favouring placental angiogenesis, a poor angiogenic state is found in 
preeclampsia. Thus, preeclampsia-associated complications might affect the cell response 
to adenosine due to altered expression and activity of adenosine receptors, membrane 
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transporters, or cell signalling mechanisms. This review summarizes the evidence available 
on the potential involvement of the adenosine in the clinical, pathophysiology, and 
therapeutic features of preeclampsia. 
  
Keywords: adenosine, adenosine receptor, preeclampsia, placenta, trophoblast, 
endothelium  
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1. Introduction 
 Adenosine is an endogenous nucleoside that plays a role as intermediary metabolite 
and is considered an extracellular signalling molecule (Eltzschig, 2009). Adenosine 
signalling controls several physiological processes in both normal and pathological 
conditions (Fredholm, 2014; Idzko et al., 2014) via the activation of four different G-
protein-coupled adenosine receptors (ARs), i.e., A1 (A1AR), A2A (A2AAR), A2B (A2BAR), 
and A3 (A3AR) (Fredholm et al., 2011). This nucleoside is synthetized at the intracellular 
and extracellular space mostly from adenosine triphosphate (ATP) but also from other 
substrates (Fredholm, 2007, 2014; Silva et al., 2016). Cell response to adenosine depends 
on the extracellular concentration of adenosine, which is mainly regulated by the activity of 
two major families of membrane transporters of nucleosides (Fredholm, 2014; Li et al., 
2012; Young, 2016) and its intracellular and extracellular metabolism (Eltzschig, 2009; 
Idzko et al., 2014; Silva et al., 2016).  
Adenosine level is higher in the third trimester of pregnancy in a normal pregnancy 
(Yoneyama et al., 2000); however, the level of this nucleoside is increased in preeclampsia 
both in the maternal and foetoplacental circulation (Espinoza et al., 2011; Takeuchi et al., 
2001; Yoneyama et al., 1996, 2002a). Preeclampsia is a pregnancy specific syndrome that 
affects 3-5% of pregnancies worldwide and is one of the main causes of maternal, foetal, 
and neonatal mortality (Duley, 2009; Mol et al., 2016; Saleem et al., 2014; Word Health 
Organization (WHO), 2013). Unveiling the pathophysiological mechanisms of 
preeclampsia is far from complete; however, a two-step model has been proposed (Roberts 
and Hubel, 2009). Poor placentation may associate with reduced placental blood flow 
(Chaiworapongsa et al., 2014), which is explained by altered placental angiogenesis and 
poor remodelling of spiral arteries (Ji et al., 2013) thus triggering a potential state of 
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placenta hypoxia or ischemia (Chaiworapongsa et al., 2014; Roberts and Hubel, 2009), 
although the hypothesis of an hypoxic or ischemic environment does not count with direct 
evidences so remains unproven. Preeclampsia also associates with dysregulation of 
endothelial function in both the maternal and foetoplacental circulation, and with 
angiogenesis, which is explained by an imbalanced concentration of proangiogenic and 
antiangiogenic factors, oxidative stress, and endoplasmic reticulum stress (ERS) 
(Chaiworapongsa et al., 2014, Charnock-Jones, 2016).  
Signalling mechanisms involved in human placental dysfunction seen in different 
types of preeclampsia are still unclear; however, compelling evidence involves adenosine 
signalling in this process. In this review we discuss the potential pathophysiological role of 
adenosine in the development of preeclampsia. 
 
2. Adenosine 
2.1.  Generation of adenosine 
Adenosine is an endogenous purine nucleoside composed of an adenine-group 
attached to a ribose sugar (Eltzschig, 2009). It is mainly generated by the breakdown of 
adenine nucleotides. Intracellularly, adenosine is generated from the hydrolysis of AMP by 
5´-nucleotidase (5´NT); however, intracellular disruption of S-adenosylhomocysteine 
(SAH) mediated by S-adenosylhomocysteine hydrolase (SAHase) also contributes to 
adenosine formation (Fredholm, 2007, 2014; Silva et al., 2016). In addition, adenosine is 
also generated at the extracellular space where degradation of adenine nucleotides, 
specifically ATP and ADP by the ectonucleotide triphosphate diphosphohydrolase 1 (also 
referred as CD39), followed by AMP hydrolysis to adenosine by ecto-5´-nucleotidase (also 
referred as CD73) (Chen et al., 2013). Therefore, adenosine level mostly depends on the 
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production of ATP and, consequently, of AMP. When ATP consumption is increased in 
relation to the ATP synthesis, thus decreasing the ATP/ADP ratio, AMP increases and 
hence adenosine production. On the other hand, two important enzymes are involved in the 
reduction of adenosine bioavailability, i.e., adenosine kinase (AK) and adenosine 
deaminase (ADA), which use adenosine to form AMP and inosine, respectively (Eguchi et 
al., 2015; Silva et al., 2016).  
Basal physiological concentration of adenosine at the extracellular space is reported 
as 30-200 nmol/L (Chen et al., 2013; Fredholm, 2014; Idzko et al., 2014). However, under 
pathological conditions such as hypoxia, ischemia, or inflammation, adenosine level could 
reach up to ~1 µmol/L as a result of increased release and generation from adenine 
nucleotides (Ballarin et al., 1991; Eltzschig, 2009; Chen et al., 2013; Fredholm, 2014; 
Idzko et al., 2014). Since these pathological conditions also result in increased extracellular 
ATP reaching 4-8 mmol/L, CD39 and CD73 activity could contribute to further increase 
extracellular adenosine generation (Chen et al., 2013). Adenosine release takes place in 
multiple cell types including endothelial cells, astrocytes, cardiomyocytes, neutrophils, and 
trophoblast cells (Fredholm, 2014). However, the main source of adenosine in plasma is 
ADP and ATP released from activated platelets (Eltzschig, 2013; Idzko et al., 2014). Thus, 
besides that determination of adenosine concentration is an important point, it is necessary 
to take into account that determination of this nucleoside’s concentration in blood may by 
altered by nucleotide release from platelets during blood sampling, a phenomenon that per 
se could result in activation of platelets. Intracellular and extracellular adenosine 
concentration is also regulated by the activity of plasma membrane nucleoside transporters 
(Young, 2016). Interestingly, other mechanisms, although not fully confirmed, include the 
release of nucleotides through pannexin or connexin hemichannels (Faigle et al., 2008; 
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Lazarowski, 2012). Thus, an equilibrated synthesis and degradation of adenosine, and 
release and uptake of this nucleoside by plasma membrane transporters seems essential to 
maintain its physiological concentrations in health and disease.  
 
2.2.  Adenosine transporters 
 Two major families of plasma membrane nucleoside transporters have been 
characterized in mammalian cells, i.e., the equilibrative nucleoside transporters (ENTs), 
which are Na+-independent and drives nucleosides in favour of a concentration gradient, 
and the concentrative nucleoside transporters (CNTs), which are Na+-dependent and drives 
nucleoside uptake following an extracellular-to-intracellular Na+ gradient (Li et al., 2012; 
Young, 2016). Four members of the ENTs family of solute carriers (SLC29A genes) have 
been reported in human tissues (hENT1, hENT2, hENT3, hENT4) (San Martin & Sobrevia, 
2006; Young, 2016). ENT1 is a protein of 456 amino acids with apparent Km of 50-200 
µmol/L for transport of purine and pyrimidine nucleosides. ENT2 protein (456 amino 
acids) transport nucleobases, such as hypoxanthine, besides purine and pyrimidine 
nucleosides, and exhibits apparent Km in the same range of ENT1 (40-150 µmol/L for 
adenosine). ENT3 protein (475 amino acids) is functional in intracellular organelles such as 
lysosomes, and transport purine and pyrimidine nucleosides in a pH-dependent manner, 
although kinetic parameters for adenosine transport have not yet been reported (Sobrevia et 
al., 2016; Silva et al., 2016; Young, 2016). ENT4 protein (530 amino acids) is a member of 
this family of membrane transporters that behaves as a polyspecific organic cation 
transporter that mediates uptake of substrates such as serotonin and dopamine more 
efficiently than adenosine. Since ENT4-mediated adenosine uptake is favoured by an acidic 
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extracellular pH, this membrane transporter might play a role in pathological conditions 
such as ischemia (Wang et al., 2012).  
 ENT1 and ENT2 are functionally the most relevant adenosine transporters in most 
cell types. Since differences between intracellular and extracellular adenosine are small 
under physiological conditions, net flow through ENTs is minimal under normal 
circumstances (Eltzschig, 2009). However, inhibition of these membrane transporters by 
either pharmacological approaches (v.g., dipyridamole, dilazep) or pathological conditions 
(v.g., ischemia, inflammation, diabetes mellitus, cancer) results in an increase in the 
extracellular adenosine concentration (Fredholm, 2014; Li et al., 2012; San Martin and 
Sobrevia, 2006; Silva et al., 2016; Sobrevia et al., 2016; Young, 2016). CNTs (SLC28A 
genes) are at least three members (CNT1, CNT2, CNT3) and show pyrimidine, purine, and 
broad selectivity, respectively (Gray et al., 2004; Young, 2016).  
 
2.3. Adenosine receptors and signalling  
ARs are widely expressed in most tissues and are implicated in the regulation of 
circulation, renal blood flow, immune system, glucose homeostasis, hyperlipidaemia, 
atherosclerosis, angiogenesis, inflammation, and ischemia-reperfusion (Borea et al., 2016; 
Chen et al., 2013). Adenosine exerts its biological effects by activating ARs subtypes 
(Fredholm et al., 2011). ARs belong to the P1 purinergic G-coupled protein receptors and 
present with seven transmembrane domains leading to modulation of the intracellular level 
of the second messenger cyclic AMP (cAMP) (Burnstock, 2006; Ledent et al., 1997). 
Under physiological conditions adenosine activates A1AR, A2AAR, and A3AR with 
effective half-maximal concentration (EC50) values varying from 0.01 to 1 µmol/L. 
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However, A2BAR requires higher concentrations of adenosine to be activated (EC50 ~24 
µmol/L) (Ledent et al., 1997).  
 A1AR and A3AR activation results in reduced intracellular cAMP level due to its 
association to adenylyl cyclase (AC)-inhibitor Gi-protein. On the other hand, A2AAR and 
A2BAR associate with AC-stimulator Gs-protein leading to cAMP synthesis (Bruns et al., 
1986; van Calker et al., 1979). It is also known that activation of the A1AR increases the 
activity of K+ channels, but blocks Ca2+ channels leading to higher intracellular Ca2+, 
activation of phospholipase C (PLC), and inositol-1,4,5-trisphosphate (IP3) synthesis 
(Dickenson et al., 1998). Activation of A2AAR increases protein kinase A (PKA) activity 
through cAMP (Fredholm et al., 2000). It is known that A2BAR stimulate the mitogen-
activated protein kinase (MAPK) activity with similar affinity as A2AAR (Schulte and 
Fredholm, 2003). Activation of A3AR associates with increased nuclear factor-κB (NF-κB) 
activity and the phosphoinositide 3-kinase (PI3K)-protein kinase B/Akt signalling pathway 
(Ochaion et al., 2009). Due to the broad range of biological effects of adenosine, regulating 
its extracellular level and its differential binding to ARs may be crucial for adenosine 
actions under physiological and pathophysiological conditions. 
 
3. Preeclampsia 
3.1. Definition  
 Preeclampsia has traditionally been diagnosed as the novo hypertension (systolic 
blood (SBP) pressure >140 mmHg or diastolic blood pressure (DBP) >90 mmHg on two 
occasions with 4-6 hours apart) and proteinuria (≥300 mg protein excretion in 24-hours 
urine collection, and alternatively a protein/creatinine ratio <0.3) appearing in the second 
half of pregnancy (Myatt and Roberts, 2015; Sibai et al., 2005). Since there is not a clear 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 11
general consensus the criteria for the diagnoses of preeclampsia have been recently 
reviewed (Phipps et al., 2016). The International Society for the Study of Hypertension in 
Pregnancy defined preeclampsia as the occurrence of new onset hypertension after 20 
weeks of gestation and the coexistence of one or more new onset events of proteinuria, 
other maternal organ dysfunction (i.e., renal insufficiency, liver, neurological or 
haematological complications), or uteroplacental dysfunction (Mol et al., 2016; Tranquilli 
et al., 2014). Nevertheless, in the absence of proteinuria preeclampsia may also be 
diagnosed as hypertension associated with one systemic complication, such as 
thrombocytopenia (<100.000/microliter), impaired liver function (elevated blood level of 
liver transaminases), new development of renal insufficiency (serum creatinine >1.1 mg/dL 
or doubling serum creatinine in the absence of other renal disease), pulmonary edema, or 
new-onset cerebral or visual disturbances (American College of Obstetricians and 
Gynecologists (ACOG), 2013; Chen et al., 2014).  
 
3.2. Clinical presentation  
Although the basic clinical feature of preeclampsia is the hypertensive disorder, the 
name of this pregnancy pathology comes from the classical progress to eclampsia, which is 
characterized by new-onset grand mal seizures (Abalos et al., 2014). Currently, incidences 
of preeclampsia and eclampsia are ~2.2 and ~0.28%, respectively. However, reported 
values are variable because different criteria and registry systems. Additional maternal 
complications of preeclampsia include abruption placenta, myocardial infarction, stroke, 
retinal injury, and combination of haemolysis, HELLP syndrome (elevated liver enzymes 
and thrombocytopenia), pulmonary edema, and acute renal or liver failure. Since maternal 
health status deteriorates as successive complications appear, preeclampsia is a typical 
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relevant cause of maternal death. On the other hand, adverse neonatal outcome are 
attributed mainly to preterm delivery, intrauterine growth restriction (IUGR), small for 
gestational age, neurologic injury, and perinatal death (ACOG, 2013; Lowe et al., 2015). 
Indeed, preeclampsia predispose to cardiovascular disease later in life in the mother and 
child (Chen et al., 2014; Epstein, 1964; Lewandowski and Leeson, 2014). Risk factors for 
developing preeclampsia are healthy nulliparous women, advanced maternal age, family or 
previous history of preeclampsia, multiple pregnancy, limited sperm exposure, or pre-
existing medical conditions such as chronic hypertension, diabetes mellitus, 
antiphospholipid antibody syndrome, thrombophilia, renal disease, high body mass index 
(BMI), or hydatidiform mole (ACOG, 2013; Tranquilli et al., 2014).  
 
3.3. Classifications 
 Preeclampsia is classified as severe or mild according to the clinical characteristics. 
Severe preeclampsia regards with >160 mmHg SBP and/or >110 mmHg DBP, without or 
with >3-5 g/L proteinuria (Tranquilli et al., 2013). An incidence of ~0.9% of severe 
preeclampsia with clinical outcome resulting in progressive deterioration of maternal and 
foetal conditions requiring early delivery is reported (Mol et al., 2016). Mild preeclampsia 
regards with 140-160 mmHg SBP, and/or 90-110 mmHg DBP, and <3 g/L proteinuria. 
However, it was recommended that the expression ‘mild preeclampsia’ be replaced by 
‘preeclampsia without severe feature’ (ACOG, 2013).  
 Preeclampsia is also classified as early onset (EOPE) or late onset (LOPE) 
preeclampsia regarding to the gestational age at the moment of diagnose of the disease (Lee 
et al., 2016). EOPE is diagnosed at <32-34 weeks of gestation (wg), but LOPE is diagnosed 
at ≥34 wg. Preeclampsia is defined as ‘preterm preeclampsia’ when <37 wg, but as ‘term 
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preeclampsia’ when >37 wg (Phipps et al., 2016; Tranquilli et al., 2013). Therefore, LOPE 
includes preterm and term pregnancy. This point highlights the severity of preeclampsia 
preferentially associated with EOPE, although these characteristics are also described in 
LOPE (Lee et al., 2016).  
 EOPE and LOPE are different forms of preeclampsia with different hemodynamics 
and aetiology (Lisonkova and Joseph, 2013; Valensise et al., 2008). EOPE prevalence is 
~0.4% (Lisonkova and Joseph, 2013) and associates with incomplete spiral artery 
remodelling, abnormal uterine Doppler, IUGR, HELLP syndrome, and maternal and 
newborn adverse outcome (Redman et al., 2014). In contrast, LOPE prevalence is ~3% 
(Lisonkova and Joseph, 2013), less distinguishable from uncomplicated pregnancy, relates 
with insulin resistance, high maternal BMI, and low vascular resistance (Roberts et al., 
2011; Valensise et al., 2008). It is proposed that LOPE result from microvillous 
overcrowding because placental growth reaches its maximal functional limit (Redman et 
al., 2014). Interestingly, it has been proposed that preeclampsia should be graded into two 
wide categories that include ‘maternal preeclampsia’ and ‘placental preeclampsia’, 
depending on whether preeclampsia is due to pre-existing maternal disorders or depends on 
factors released from the placenta to maternal circulation, respectively (Amaral et al., 2015; 
Ness and Roberts, 1996; Phipps et al., 2016). Since more of the clinical features of 
preeclampsia disappear with delivery of the newborn and the placenta, the concept of 
‘placental preeclampsia’ seems more plausible and is generally accepted. Nonetheless, 
‘maternal preeclampsia’ is a possibility to consider especially when there are increasing 
reports documenting that pregestational and gestational health status of the mother is 
determinant for a healthy pregnancy (Sobrevia et al., 2016).  
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3.4. Pathophysiological mechanisms  
In normal pregnancies, the development of a normal uteroplacental circulation 
occurs with uterine spiral arteries remodelling where the trophoblast invades the arterial 
wall and transforms the spiral arteries from high resistance to low resistance vessels, thus 
assuring adequate perfusion of the placenta. Placentas from pregnancies with advanced 
preeclampsia show vascular alterations (Sircar et al., 2015). Studies in human and animal 
experimental models hypothesize that preeclampsia results from altered uteroplacental 
circulation leading to uteroplacental ischemia (Phipps et al., 2016). In preeclampsia, the 
remodelling of the uterine spiral arteries is altered (Figure 1) and subsequent reduction in 
placental circulation and development of placental ischemia is feasible (Brosens and 
Renaer, 1972). The precise mechanisms involved in abnormal transformation of uterine 
spiral arteries in preeclampsia are not fully understood.  
In addition to abnormal placentation other factors are also involved in the 
pathophysiological mechanisms of preeclampsia. However, these factors may not reflect 
definitive or unique mechanisms of all, but for a fraction of patients with this disease. 
These factors include (Figure 1): (i) a state of oxidative stress where hypoxia results in 
higher expression of hypoxia-inducible factor 1α (HIF-1α) and excessive synthesis of 
oxidative stress markers (Rajakumar et al., 2004). The increase in HIF-1α initiates a nuclear 
factor κB (NF-κB)-dependent inflammatory response within the vasculature coursing with 
endothelial dysfunction (Mohaupt, 2007) and enhanced state of oxidative stress (Redman & 
Sargent, 2009). Oxidative stress and inflammation would then be involved in the initiation 
and progression of hypertension in preeclampsia (Mate et al., 2012). (ii) Angiogenesis (i.e., 
formation of new blood vessels from pre-existing ones) is essential for a successful 
pregnancy (Maynard et al., 2013), and numerous studies demonstrate that an imbalance 
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between angiogenic and antiangiogenic factors in favour of antiangiogenesis is involved in 
the pathogenesis of preeclampsia. Two antiangiogenic factors, i.e., the soluble (Fms)-like 
tyrosine kinase 1 (sFlt1) and soluble endoglin (sEng), are elevated in the plasma of women 
with preeclampsia (Powe et al., 2011). sFlt1 is a splice variant of the pro-angiogenic 
vascular endothelial growth factor (VEGF) receptor 1 (VEGFR-1) acting as antagonist of 
VEGF and placental growth factor. Several isoforms of sFlt1 have been reported, however 
sFlt1-14 isoform predominates in the placenta and serum in women with severe 
preeclampsia (Sela et al., 2008). sEng is a cell-surface co-receptor of transforming growth 
factor β1 (TGF-β1) and TGF-β3 inducing migration and proliferation of endothelial cells 
(Venkatesha et al., 2006). (iii) Antibodies to type-1 angiotensin receptor (AT1-Ab) have 
been detected in the serum of a very minor subset of women with preeclampsia (not a 
definition of the subtype of preeclampsia was given) (Wallukat et al., 1999). AT1-Ab 
activates type-1 angiotensin receptors (AT1) in vascular endothelial, smooth muscle, and 
mesangial cells. AT1 activation leads to hypertension, proteinuria, and glomerular capillary 
endotheliosis in pregnant rats (Zhou et al., 2008). AT1-Ab exposure of these animals and in 
human villous explants result in increased sFlt1 and sEng thought to contribute to renal 
glomerular lesion and inflammatory response ending in impaired placental angiogenesis. 
Moreover, AT1 activation by AT1-Ab causes increased activity of NADPH oxidase, which 
is responsible for the generation of superoxide anion leading to oxidative stress (Xia and 
Kellems, 2013). Therefore, a functional link between excessive angiotensin, oxidative 
stress, inflammatory cytokines, and antiangiogenic factors is likely in the pathogenesis of 
preeclampsia. (iv) Endoplasmic reticulum stress (ERS) is also involved in preeclampsia. 
Abnormal microenvironmental conditions, such as hypoxia, lead to ERS and activate a 
series of highly conserved signalling pathways referred as the Unfolded Protein Response 
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(UPR). These phenomena also lead to growth arrest and apoptosis of the trophoblast. 
Apoptosis induces the release of microparticles and nanoparticles into the maternal 
circulation, activates the immune system, and triggers pro-inflammatory pathways (Lian et 
al., 2011).   
 
4. Adenosine in the pathophysiology of preeclampsia  
4.1. Adenosine concentration in preeclampsia 
 
Maternal adenosine concentration 
Pregnancy courses with changes in the maternal plasma concentration of adenosine, 
being higher in the third trimester compared with the first or second trimesters of pregnancy 
in a normal pregnancy (Yoneyama et al., 2000). Activated platelets contribute largely to the 
increase in plasma adenosine concentration and are the major source of adenosine in the 
maternal circulation (Figure 2) (Holthe et al., 2004; Yoneyama et al., 2000). Thus, 
adenosine release from activated platelets could be a factor leading to overestimation of 
basal adenosine concentration when collecting blood samples. Although ATP concentration 
is not increased in the plasma from pregnant women (Bakker et al., 2007), increased CD39 
activity in platelets is reported (Leal et al., 2007). In addition, plasma CD73 activity is 
responsible for enhancing the maternal plasma adenosine concentration (Alvi et al., 1988; 
Bacq et al., 1996; Yoneyama et al., 2002b). Since ADA activity is crucial to maintain 
physiological concentrations of adenosine its activity complements CD39 and CD73 
activity in this phenomenon (Silva et al., 2016). Alternatively, it is reported that incubation 
of HUVECs from normal pregnancies to a culture medium containing 25 mmol/L D-
glucose causes an overexpression of the general transcription factor specific protein 1 (Sp1) 
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(Puebla et al., 2008). Increased Sp1 expression was associated with reduced expression of 
SLC29A1 leading to reduced hENT1 protein abundance and activity. The latter resulted in 
extracellular accumulation of adenosine. Since Sp1 is reported to maintain CD39 
expression (Eltzcshig, 2009; Hart et al., 2011), adenosine formation due to increased CD39 
activity may be favoured from overexpression or higher activity of Sp1. A similar 
phenomenon could results in response to HIF-1α activation since this transcriptional factor 
increases the expression of CD39 and CD73 (Hart et al., 2011; Lu et al., 2013; Tak et al., 
2016). However, the role of ADA activity even in normal pregnancies is confusing since it 
is shown as increased (Henkiewicz and Michalski, 1971; Mokhatari et al., 2010), decreased 
(Bahadir et al., 2011; Jaqueti et al., 1990; Yoneyama et al., 2003), or unaltered (Suzuki et 
al., 2002). In mild and severe preeclampsia the maternal serum ADA2 isoform activity is 
higher than in normal pregnancies (Kafkasli et al., 2006; Karabulut et al., 2005; Kurdoglu 
et al., 2012; Yoneyama et al., 2002c). Since ADA activity increases cell-mediated 
immunity and is higher in preeclampsia it may favour an ameliorative effect of adenosine 
on immune response in this disease (Dekker and Sibai, 1999). It is likely that elevated ADA 
activity in pathological conditions is a mechanism to regulate the excessive maternal 
adenosine concentration avoiding its cytotoxicity as a result of this phenomenon. On the 
other hand, there are not reports regarding AK activity in the maternal blood in 
preeclampsia. 
Increased adenosine concentration in the maternal blood in preeclampsia (Espinoza 
et al., 2011; Shinagawa et al., 2002; Takeuchi et al., 2001; Yoneyama et al., 1996, 2002a) 
may result from potential hypoxia and ischemia (Chaiworapongsa et al., 2014), formation 
of microthrombos, or increased catecholamine secretion. As mentioned, other explanation 
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is platelet activation in preeclampsia, a phenomenon leading to release of larger amounts of 
purine nucleotides than in normal pregnancies (Coade and Pearson, 1989; Macey et al., 
2010). Interestingly, ATP concentration is higher in maternal plasma from women with 
EOPE and severe preeclampsia (Bakker et al., 2007). Since maternal plasma CD73 activity 
is increased in women with mild and severe preeclampsia compared with normal 
pregnancies, this enzyme may enhance AMP dephosphorylation to form adenosine in these 
pathologies (Yoneyama et al., 2002b). The mechanisms leading to elevated maternal 
plasma CD73 activity are unknown. However, a role for hypoxia, interleukin 1β (IL-1β), 
tumour necrosis factor α (TNF-α), and norepinephrine production in this phenomenon was 
proposed (Kitakaze et al., 1995; Raatikainen et al., 1994; Savic et al., 1990).  
 
Foetoplacental adenosine concentration  
Preeclampsia also associates with increased adenosine concentration in the 
foetoplacental circulation (Figure 2) (Espinoza et al., 2011; Yoneyama et al., 1996, 2002a). 
This phenomenon relates with abnormal uterine artery Doppler, i.e., altered pulsatility 
index, in women with preeclampsia. Unfortunately, there are not reports simultaneously 
addressing adenosine concentration in paired sampling from umbilical blood and from the 
mother in preeclampsia, thus, it is not possible to establish a potential correlation between 
adenosine concentration changes in the maternal and foetus circulation in preeclampsia.  
It was shown that syncytiotrophoblast (STB)-derived CD73 enhances adenosine 
generation in placental tissue (Iriyama et al., 2015; Matsubara et al., 1987; Matsubara and 
Sato, 2001). Since STB is most likely the largest source of CD73 and because plasma 
membrane fractions derived from STB are released into the maternal circulation, this 
placental enzyme could be a candidate as a marker for adenosine formation in this organ in 
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preeclampsia (Matsubara et al., 2001). Interestingly, CD73 is an enzyme that is induced by 
hypoxia and inflammation (Eltzschig et al., 2003). Hypoxia and inflammation-induced 
CD73 activity result in generation of an adenosine-dependent anti-inflammatory profile in 
human umbilical vein endothelial cells (HUVECs) (Li et al., 2008). Thus, not only STB, 
but also the macrovascular endothelium from the placenta is responsive, potentially via a 
similar mechanism, to these abnormal environmental conditions.  
Adenosine concentration in the umbilical vein is maintained by ADA activity (Silva 
et al., 2016). Interestingly, ADA activity is higher in umbilical vein blood in mild and 
severe preeclampsia compared with normal pregnancies (Kafkasli et al., 2006; Karabulut et 
al., 2005). The latter findings should result in reduced adenosine concentration in the 
umbilical vein blood. However, ADA activity was initially reported as lower at term in the 
foetoplacental circulation in normal pregnancies (Sim and Maguire, 1972), thus, supporting 
the possibility that adenosine concentration will be elevated at this stage of pregnancy. 
Therefore, it is unclear whether ADA activity is a significant factor contributing to the 
increase in placental adenosine concentration in women with preeclampsia. Meanwhile, AK 
activity in the foetoplacental unit from preeclampsia remains unclear.  
   
4.2. Adenosine transporters in foetoplacental tissue in preeclampsia 
 The placenta exerts a crucial role in the regulation of the foetal-maternal exchange 
of nutrients. The first step for any substrate to cross the human placenta from the maternal 
into the foetal blood is the transport across the STB. The STB is an epithelial-like structure 
highly polarized with apical (also referred as brush-border or microvillus, facing maternal 
blood) and basal (facing foetoplacental microvasculature) plasma membranes. Maternal 
substrates have to cross the villous stroma and foetal capillary endothelium to reach the 
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foetal circulation (Desforges and Sibley, 2010). The expression of carrier-mediated 
nucleoside transport at both sides of the placenta was first reported in guinea pigs (Wheeler 
and Yudilevich, 1988). Adenosine and uridine influx was described by saturable kinetics 
with apparent Km ~150 µmol/L, Na+-independent, and with symmetrical distribution in the 
apical and basal plasma membranes in STB (Barros et al., 1999). Most members of the 
SLC28A coding for human CNTs (hCTNs) and SLC29A coding for hENTs families are 
described in the human placenta (Errasti-Murugarren et al., 2009; Govindarajan et al., 
2007; Gray et al., 2004; Nishimura et al., 2012). Interestingly, an absorptive-like model for 
vectorial flux of nucleosides via CNTs at the apical and ENTs at the basal membrane of the 
STB was proposed. However, mother-to-foetus transplacental transfer of nutrients may also 
require only ENTs located at the apical and basal plasma membranes (Govindarajan et al., 
2007).  
  Only few studies address the effect of preeclampsia on adenosine transport and its 
relevance in the modulation of adenosine-mediated vascular responses. In normal 
pregnancies, the relative contribution of hENT2 for overall adenosine transport is lower 
than hENT1 in STB, HUVECs, and human umbilical artery smooth muscle cells (Escudero 
and Sobrevia, 2008). However, a similar contribution of both hENTs subtypes is reported 
in primary cultures of hPMECs (Escudero et al., 2008). Interestingly, transport activity of 
hENT1 was reduced, but hENT2 was increased in hPMECs from preeclampsia (EOPE and 
LOPE in a mix) compared with normal pregnancies (Figure 2). These results were 
paralleled by similar changes in SLC29A1 and SLC29A2 expression and the abundance of 
the corresponding protein transcripts. Interestingly, these alterations caused by 
preeclampsia require activation of A2BAR. Thus, modulation of adenosine transport is a 
mechanism that regulates adenosine’s broad biological effects following activation of ARs, 
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a mechanism that could be determinant in preeclampsia. The potential modulation of 
nucleoside transporters by ARs activation could be a compensatory mechanism to reduce 
the abnormally elevated concentrations of adenosine in the foetoplacental microcirculation 
in preeclampsia. However, since at term the concentration of adenosine is still elevated, this 
potential compensatory mechanism attempting to expedite adenosine removal from the 
extracellular space is not enough to reverse into physiological concentrations of this 
nucleoside.  
 
4.3. Adenosine receptors and signalling in foetoplacental tissue in preeclampsia 
 Expression of ARs is altered in the human foetoplacental unit in preeclampsia 
(Table 1). Most of the studies report increased ARs mRNA level and protein abundance in 
the human placenta and umbilical cord in this disease. Depending on differential activation 
of ARs, adenosine regulates multiple processes involved in the pathophysiology of 
preeclampsia, including the vascular tone, angiogenesis, cell proliferation, endothelial 
permeability and inflammation, and redox balance (Table 2). Adenosine causes 
vasodilation or vasoconstriction depending on the specific site of action in the 
foetoplacental vascular bed (Silva et al., 2016). Adenosine effects are mainly mediated by 
activation of A2AAR and A2BAR (Guzmán-Gutiérrez et al., 2012, 2016; Rogers et al., 2014; 
Salsoso et al., 2015). However, few studies address ARs activation and the potential 
involvement of this phenomenon in the altered response to adenosine in placentas from 
preeclampsia. Since (i) vasodilation or vasoconstriction in response to adenosine in the 
placenta depends on oxygen tension (Read et al., 1993), (ii) hypoxia upregulates A2AAR 
and A2BAR expression in villous placental explants (von Versen-Höynck et al., 2009), and 
(iii) disrupted oxygen sensing occurs in placentas from EOPE pregnancies (Rolfo et al., 
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2010), we speculate on the possibility that differential A2AAR and A2BAR expression might 
be involved in the different ability to respond to a potential hypoxia state in this pathology. 
However, we emphasize the fact that not a direct demonstration of hypoxia environment in 
the placental tissue in preeclampsia is yet reported.  
ARs promoters contain hypoxia response elements (St Hilaire et al., 2009). Hypoxia 
increases A2AAR and A2BAR expression via a mechanism that involves differential 
modulation by HIF-2α and HIF-1α, respectively. Although some studies report 
upregulation of all ARs subtypes (von Versen-Höynck et al., 2009), others show an 
increase only in A2AAR (Kurlak et al., 2015) in the placenta from preeclampsia. It is 
conceivable that preeclampsia may alter the expression of these receptors in the 
foetoplacental tissue. However, when looking at protein abundance it is important to 
consider that antibodies presenting weak species- and tissues-specificity may alter the 
interpretation of the results. Nothing is mentioned in the reported studies about the 
possibility that increased or decreased response of ARs subtypes may be an additional 
feature to take in consideration beyond a change in ARs protein abundance. Since some 
studies report changes in mRNA level by either not quantitative, semi-quantitative, or 
quantitative experimental approaches, the results regarding ARs expression level in 
preeclampsia may also be misinterpreted and should be taken with caution.  
Despite the fact that A2BAR activation in LOPE was suggested as a potential 
compensatory mechanism for this disease-associated foetoplacental endothelial dysfunction 
(Escudero et al., 2008), the effect of activating A2BAR on the capacity of trophoblast to 
migrate, proliferate, and invade in vitro is contradictory (Darashchonak et al., 2014a,b). 
Studies in HUVECs from preeclampsia (apparently from LOPE pregnancies) show 
impaired NO/VEGF signalling pathway in response to a general activator of A2BAR, thus 
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hindering the capacity of these cells to proliferate and migrate (Acurio et al., 2014). One of 
the proposed explanations for this finding was that A2BAR protein was functionally altered 
in this type of preeclampsia; however, the concentration of the general ARs agonist used in 
these studies (10 µmol/L 5′-N-ethylcarboxamidoadenosine (NECA)) will activate all the 
ARs subtypes, thus, not a specific A2BAR effect is expected. A more direct involvement of 
A2BAR in the placental-alterations associated with preeclampsia is reported in genetically 
engineered pregnant mice where an elevated adenosine concentration was exclusively 
found in the placenta, and in a pathogenic autoantibody-induced preeclampsia mouse model 
(Iriyama et al., 2015). Elevated adenosine and subsequent activation of A2BAR was enough 
to reproduce key components of preeclampsia such as hypertension, proteinuria, increased 
sFlt1, impaired placental vasculature reactivity, and IUGR in these experimental models. 
These findings were supported by results showing that preeclampsia phenotype was 
successfully reverted after genetic A2BAR deletion in these animals. Thus, expression of 
functional A2AAR and A2BAR in the placenta is determinant in preeclampsia.  
 
4.4. Role of adenosine in general mechanisms of preeclampsia development 
 
Adenosine and angiogenesis 
 Adenosine regulates angiogenesis and vasculogenesis via activation of all ARs 
subtypes (Rolland-Turner et al., 2013; Ryzhov et al., 2008; Vandekeere et al., 2015). 
Activation of A1AR induces the expression of VEGF from monocytes, thus indirectly 
promoting angiogenesis (Clark et al., 2007). A1AR activation also directly associates with 
pro-angiogenic processes, promoting the association of embryonic endothelial progenitor 
cells to the vascular endothelium, suggesting a role for this type of ARs subtype in 
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vasculogenesis (Ryzhov et al., 2008). Activation of A2AAR potentiates angiogenesis by 
stimulating VEGF-dependent cell proliferation and migration in HUVECs (Escudero et al., 
2013), and by reducing the anti-angiogenic effect of matrix protein thrombospondin-1 in 
human microvascular endothelium (Desai et al., 2005). A2AAR activation also increases 
VEGF release, but decreases sFlt1 expression from macrophages (Pinhal-Enfield et al., 
2003). Thus, activation of A2AAR is a factor that results in VEGF-dependent angiogenesis. 
A2BAR are also associated with stimulation of angiogenesis since its activation promotes 
endothelial cell proliferation, migration, and tube formation, a phenomenon involving 
induction of VEGF, IL-8 and basic fibroblast growth factor expression (Feoktistov et al., 
2002; Grant et al., 1999; Ryzhov et al., 2014). Thus, adenosine or adenosine-induced 
factors via activation of these ARs subtypes is required for angiogenesis and 
vasculogenesis.  
 Activation of A3AR also directly and indirectly regulates angiogenesis. The 
signalling cascade triggered by activation of A3AR inhibits migration and tube formation 
in HUVECs and mouse embryonic stem cells differentiated to endothelial cells (Kim et al., 
2013). The effects of A3AR activation lead to a decrease in ex vivo microvessels sprouting 
in cultured mouse aortic rings. A3AR activation also leads to indirect stimulation of 
angiogenesis via a mechanism that includes adenosine-dependent IL-6, IL-8, and VEGF 
increased secretion from mast cells (Feoktistov et al., 2003; Rudich et al., 2015). Thus 
adenosine exerts angiogenic regulatory effects mainly potentiating the formation and 
maturation of de novo vascular networks, but it is also involved in the modulation of anti-
angiogenic processes. Paradoxically, mild and severe preeclampsia associates with an anti-
angiogenic state, but a high adenosine concentration at the foetoplacental (Escudero and 
Sobrevia, 2012; Espinoza et al., 2011) and maternal (Yoneyama et al., 2002a) circulation is 
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found. Since the expression of all ARs is higher in human placenta from preeclampsia 
(Table 1), a higher adenosine-dependent signalling meaning a pro-angiogenic state is 
expected at this condition. We hypothesize that these contradictory findings could relate 
with a less sensitive or abnormal ARs-associated signalling in response to an elevated 
concentration of adenosine in preeclampsia. However, the exact mechanisms explaining 
this apparent paradox, as well as whether elevated placental adenosine concentration is part 
of a causal or an effect of preeclampsia, remain unclear.   
 
Adenosine and trophoblast invasion 
 ADA deficient mouse pups were shown to dye at post-implantation period 
suggesting that a higher adenosine concentration may inhibit placental development 
(Blackburn et al., 1997). Thus, adenosine may be a factor involved in trophoblast 
proliferation, migration/invasion, and differentiation in preeclampsia. This disease also 
shows with increased ARs expression in cytotrophoblasts (von Versen-Hoynck et al., 
2009). A3AR expression is higher in villous explants from preeclampsia compared with 
normal pregnancies, a phenomenon that was paralleled by a lower metaloprotease 2 (MMP-
2) and MMP-9 expression (Kim et al., 2008; von Versen-Hoynck et al., 2009). Since 
activation of A3AR restored the expression of these MMPs, it is feasible that A3AR 
activation-dependent increase in these MMPs activity in the trophoblast could be a 
mechanism by which adenosine regulates trophoblast proliferation, migration/invasion, and 
differentiation in preeclampsia. The fact that increased A3AR, but reduced MMP-1 and 
MMP-9 is seen in preeclampsia, may reflect a less functional adenosine receptor subtype in 
the placenta from this pathology. Other studies suggest a role for hypoxia on trophoblast 
invasion (Chaiworapongsa et al, 2014). However, this environmental condition is shown to 
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reduce (Kilburn et al., 2000; Onogi et al., 2011) or increase (James et al., 2006) trophoblast 
invasion. Since trophoblast invasion occurs within decidual tissues, which is vascularized 
and supplied with oxygen, it is a phenomenon that occurs under normoxia. Because oxygen
 
tension in the placenta tissue has not been directly addressed, not a clear conclusion 
regarding hypoxia as a factor increasing trophoblast invasion can be given.  
 
Adenosine and cellular stress and inflammation  
Cellular stress and inflammation are conditions involved in the pathophysiology of 
preeclampsia (Elliot, 2016; Gupta et al., 2005; Redman and Sargent, 2009). It is proposed 
that a lower blood perfusion resulting from altered trophoblast invasion leads to cellular 
stress in the placenta. Increased generation of reactive oxygen-derived species (ROS) under 
hypoxia is associated to ERS, placental barrier dysfunction, and release of trophoblast-
released inflammatory mediators into the maternal blood (Baumwell and Karumanchi, 
2007; Elliot, 2016). These findings are supported by other results showing increased 
oxidative stress markers in placental tissues from preeclampsia (Chamy et al., 2006; Many 
et al., 2000; Roberts and Hubel, 1999; Sikkema et al., 2001; Uotila et al., 1993). However, 
local variations of oxygenation may well resemble an ischemia-reperfusion mechanism of 
the damaged placenta (Burton and Jauniaux, 2004). Adenosine is shown to play a 
protective role in hypoxia/reperfusion preconditioning in different clinical settings (Chen et 
al., 2013; Eltzschig, 2009). Thus, elevated concentration of adenosine in women with 
preeclampsia could be a protective or compensatory mechanism to the cellular stress in this 
disease. For example, 1,3-dipropyl-8-sulfophenylxanthine (DPSPX, a general ARs 
antagonist) induces oxidative stress-dependent hypertension in rats (Sousa, 2008). Thus, 
increased adenosine concentration and ARs expression might play a protective role in 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 27
oxidative stress-associated hypertensive disorders such as preeclampsia. Unfortunately, this 
hypothesis has not yet been directly evaluated in humans or animal models of preeclampsia. 
Ischemia-reperfusion and hypoxia induce ERS by impairing Ca2+ homeostasis 
(Yung et al., 2014). Intraluminal conditions of the endoplasmic reticulum, including a high 
concentration of ionic Ca2+, allow normal post-translational protein folding. Disturbances in 
these conditions lead to accumulation of misfolding proteins within the lumen, triggering 
ERS signalling and activation of UPR. Interestingly, women with preeclampsia accumulate 
misfolding proteins and show increased ERS markers in the placenta (Burton et al., 2009) 
and urine samples (Buhimschi et al., 2014). Although no evidence has been reported about 
a potential relationship between adenosine and ERS in preeclampsia, it is a plausible 
mechanism since adenosine is proposed as a potential therapeutic agent for the prevention 
and treatment of oxidative stress and ERS in neurodegeneration (Olatunji et al., 2016). 
Additionally, in primary cultures of HUVECs from gestational diabetes mellitus the 
expression and activity of the transcription factor complex C/EBP homologous protein 10, 
an ERS marker (Hetz, 2012), is increased leading to repression of the SLC29A1 expression 
and extracellular adenosine accumulation (Farías et al., 2010). Thus, increased extracellular 
adenosine concentration in preeclampsia may be a mechanism leading to ERS in the human 
placenta from this disease.   
Preeclampsia is understood as the extreme end of a continuum of maternal systemic 
inflammatory responses caused by the pregnancy itself (Borzychowski, 2006). Since the 
adenosine biological actions mediated by ARs and the role of adenosine membrane 
transporters in this phenomenon have been related to immune-dependent diseases (Dong et 
al., 2016), this mechanism may be implicated in events leading to preeclampsia. 
Interestingly a prevention of preeclampsia-like syndrome following transfer of activated 
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Th1 cells in mice overexpressing CD39 was reported (Mcrae et al., 2013). Since CD39 is 
the main ectonucleotidase expressed in the placenta, its overexpression might associate 
with increased extracellular concentration of adenosine leading to activation of ARs, thus, 
dampening the immune response. The precise mechanisms by which potentially adenosine 
is involved in reducing the immune response in the placenta in preeclampsia are unknown.  
 
Adenosine and circadian rhythm proteins  
 Caffeine consumption causes a delay of the circadian melatonin rhythm in humans, 
an effect that was attributed to cAMP-dependent altered mechanisms due to activation of 
ARs (Burke et al., 2015). It is known that adenosine is a potent cardioprotector (Gile and 
Eckle, 2016) and the role of A2BAR activation in ischemic preconditioning-mediated 
cardioprotection is reported (Gile and Eckle, 2016). A2BAR is under regulation by ischemia 
in the heart in humans (Eckle et al., 2012) and protects this tissue during ischemia-
reperfusion injury activating inflammatory cells (Koeppen et al., 2012). Adenosine 
downstream signalling mechanisms also lead to activation of the circadian clock gene 
Period 2 (Per2) in humans (Eltzschig et al., 2013; Gile and Eckle, 2016; Valenzuela et al., 
2015). Per2 is a member of the Period family of genes expressed in 24-hours circadian 
pattern at the suprachiasmatic nucleus at the hypothalamus, acts as cofactor for the control 
of other transcription factors, and regulates many metabolic processes (Gile and Eckle, 
2016). Interestingly, Per2, as well as other endogenous pacemakers such as circadian 
locomoter output cycles kaput, brain and muscle arnt-like 1, and cryptochrome 1 mRNAs, 
are expressed in the human placenta from normal pregnancies (Pérez et al., 2015; 
Valenzuela et al., 2015). As described, A2BAR plays a role in preeclampsia and its 
activation may, at least in part, explain this disease’s associated characteristics (Iriyama et 
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al., 2015). Preeclampsia also associates with increased A2BAR expression in the human 
placenta (Iriyama et al., 2015; von Versen-Höynck et al., 2009) and HUVECs (Acurio et 
al., 2014); however, HUVECs from LOPE show reduced A2AAR expression (Salsoso et al., 
2015). Thus, biological actions of adenosine are expected to preferentially result from 
A2BAR activation in preeclampsia. A recent study shows that pregnant women with 
preeclampsia have lower salivary melatonin release through out the day in a circadian 
rhythm variation (Shimada et al., 2016). Additionally, the rhythm of melatonin blood 
concentration in women with preeclampsia was lower compared with women coursing with 
a normal pregnancy (Bouchlariotou et al., 2014). Interestingly, shift work resulting in sleep 
deprivation or circadian rhythm disruption in pregnant women with preeclampsia was 
associated with increased risk of foetuses small for gestational age, low birth weight, and 
preterm birth (Bonzini et al. 2011). Thus, a circadian rhythm is present in human gestation 
and seems to be involved in preeclampsia (Bonzini et al., 2011; Reiter et al., 2014). 
Whether activation or inhibition of A2BAR, or other ARs subtypes, result in modulation of 
circadian rhythm proteins in the placenta from preeclampsia is not yet addressed.  
 
5. Concluding remarks 
Adenosine modulates multiple processes involved in the pathophysiology of 
preeclampsia. Preeclampsia shows with increased adenosine concentration at the maternal 
and foetoplacental circulation. Moreover, the network of adenosine plasma membrane 
transporters (mostly hENT1) and adenosine receptors (mostly A2AAR and A2BAR), and 
their associated intracellular signalling seems involved in the development of preeclampsia 
(Figure 3). The mechanisms include adenosine regulation of the release of pro-angiogenic 
and anti-angiogenic factors, trophoblast invasion, transformation of the spiral arteries, 
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cellular stress, and inflammation associated with a potential, not yet directly demonstrated 
placental ischemia and hypoxia in preeclampsia. However, even when multiple associations 
have been established among adenosine concentration and clinical features in this disease, 
further studies are required to understand the molecular regulation and functional 
consequences of adenosine signalling in the human foetoplacental unit. The very short half-
life of this nucleoside might relegate its actions only to tissue locations that are close to 
where it is released, such as the placental vascular bed. Thus, it is difficult to interpret 
alterations in the biology of the placenta adenosine pathway in relation with the clinical 
manifestations of preeclampsia in the mother. Instead, changes in circulating adenosine 
might be upstream of the pathological processes in preeclampsia, rather than being a 
starting point in the disease. Unveiling the signalling pathways that are susceptible of 
regulation by specific ARs activation or inhibition is a crucial step in the search for 
potential approaches to prevent the development of preeclampsia. We are not aware of 
currently available information regarding on-going clinical trials or other sort of massive 
research to address this possibility. However, the role of elevated adenosine in the 
pathophysiology of the disease cannot be fully understood using only in vitro cell and 
organ culture systems. It is crucial that in vivo studies are done to test global effects of 
adenosine signalling in preeclampsia.  
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Figure 1. Preeclampsia and associated factors in the human placenta. The human 
placenta in preeclampsia shows several alterations starting with an abnormal 
regulation of the remodelling of the uterine spiral arteries. This characteristic of the 
pathology may result in abnormal supply of oxygen to the placenta leading to a 
potential, not directly confirmed (?) state of hypoxia or ischemia causing activation of 
several mechanisms resulting in a high level of oxidative stress and inflammation. 
This phenomenon is suggested to result from increased () expression and activity of 
hypoxia inducible factor 1a (HIF-1a) that ends in nuclear factor κB (NF-κB)-
dependent inflammation. Oxidative stress results in endothelial dysfunction and most 
likely increases the endoplasmic reticulum stress (ERS), a condition evidenced by 
increased unfolded protein response (UPR) and trophoblast apoptosis. ERS is also 
accompanied by a higher proinflammatory state in the placenta. Both oxidative stress 
and ERS are conditions that could result or be potentiated by the increase in the 
activity of the NADPH oxidase in response to activation of angiotensin receptor 1 
(AT1) most likely through the generation of superoxide anion (O2.–). AT1 receptors 
activation also increases the expression and activity of the antiangiogenic factors 
soluble (Fms)-like tyrosine kinase 1 (sFlt1) and soluble endoglin (sEng), a 
phenomenon resulting in reduced angiogenesis. The reduced synthesis and release of 
the pro-angiogenic vascular endothelial growth factor (VEGF) result in further 
reduction in angiogenesis in the human placenta. Whether the reduced angiogenesis 
phenomena are the cause of altered remodelling of uterine spiral arteries or the other 
way round, is unknown (double heads red arrow). Solid light blue arrows suggest a 
potential dependency of a sequence of phenomena that characterizes preeclampsia as 
shown.  
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Figure 2. Factors increasing adenosine concentration in the mother and in the 
foetoplacental tissue in preeclampsia. Adenosine plasma concentration in the 
mother and in the foetoplacental tissue is abnormally high in preeclampsia compared 
with normal pregnancies. Among the factors described in the literature to sustain this 
increase (red arrows) in the adenosine concentration in the mother (Mother) are 
hypoxia due to a generalized high consumption of oxygen by the mother and the 
growing foetus. Other factors include platelets activation leading to release of ATP, 
and perhaps directly adenosine (Silva et al., 2016), which is then hydrolyzed to AMP 
and adenosine as a result of the increased expression and activity of the 
ectonucleotide triphosphate diphosphohydrolase 1 (CD39) and ecto-5´-nucleotidase 
(CD73). Increased microthromobos formation and release of catecholamines (v.g., 
norepinephrine) are factors that contribute to adenosine accumulation in the maternal 
circulation. Preeclampsia also courses with a generalized inflammatory state where 
increased biological actions of factors such as interleukin 1β (IL-1β) and tumour 
necrosis factor α (TNF-α) are proposed to result in higher adenosine concentration. 
The concentration of adenosine in the maternal circulation is reduced (dotted red 
arrow) by adenosine deaminase (ADA) activity whose activity seems elevated in 
preeclampsia. Sources of adenosine in the foetoplacental tissues (Foetoplacental 
tissues) in preeclampsia regards with a potential, but not directly demonstrated 
hypoxia or ischemia (?) condition. Additionally, increased concentration of ATP and 
ADP together with a higher expression of CD73 derived from syncytiotrophoblast 
(STB). The role of ADA in this phenomenon is controversial and increased ADA 
activity could result in reducing (dotted red arrow), but reduced () ADA activity 
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results in increasing adenosine concentration in the foetoplacental tissue in 
preeclampsia.  
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 65
Figure 3. Potential involvement of adenosine in the adverse outcome in preeclampsia. 
Preeclampsia associates with maternal hypoxia (which is still uncertain (?)) resulting 
in reduced () expression and activity of human equilibrative nucleoside transporters 
1 (hENT1), thus reducing (dotted blue arrow) adenosine uptake. This phenomenon 
results in accumulation () of adenosine in the extracellular space (among other 
factors as sources of adenosine, see Figure 2). Preeclampsia also associates with a 
higher hypoxia-inducible factor 2α  (HIF-2α)–dependent A2A (A2AA ) and hypoxia-
inducible factor 1α  (HIF-1α)–dependent A2B (A2BAR) adenosine receptor 
expression. Under this pathological condition A2AAR activation results in lower 
synthesis and release of the pro-angiogenic vascular endothelial growth factor 
(VEGF) leading to reduced angiogenesis in the placenta. On the other hand, A2BAR 
activation results in lower synthesis of nitric oxide (NO) leading to reduced 
vasodilation and increased vasoconstriction. Thus, reported adenosine-dependent 
mechanisms via A2AAR and A2BAR activation accounting for an adverse outcome in 
preeclampsia. IUGR, intrauterine growth restriction.  
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table 1. Effect of preeclampsia on adenosine receptors expression in human foetoplacental tissue. 
 
Receptor 
subtype 
Type of 
preeclampsia  
Tissue or 
cells 
Effect on 
mRNA 
expression 
Effect on 
protein 
expression 
References 
      
A1AR EOPE Placenta Increased Increased von Versen-Höynck et al., 2009 
A1AR LOPE Placenta Increased Increased von Versen-Höynck et al., 2009 
A2AAR EOPE Placenta Increased Increased von Versen-Höynck et al., 2009 
A2AAR LOPE Placenta Increased Increased von Versen-Höynck et al., 2009 
A2AAR LOPE HUVECs n.m. Decreased Salsoso et al., 2015 
A2AAR LOPE Placenta n.m. Increased Kurlak et al., 2015 
A2BAR EOPE Placenta Increased Increased von Versen-Höynck et al., 2009 
A2BAR LOPE Placenta Increased Increased von Versen-Höynck et al., 2009 
A2BAR LOPE Placenta Increased Increased Iriyama et al., 2015 
A2BAR LOPE HUVECs n.m. Increased Acurio et al., 2014 
A3AR EOPE Placenta  Increased Increased von Versen-Höynck et al., 2009 
A3AR LOPE Placenta  Increased Increased von Versen-Höynck et al., 2009 
A3AR LOPE Placenta n.m. Increased Kim et al., 2008 
 
A1AR, A1 adenosine receptor; A2AAR, A2A adenosine receptor; A2BAR, A2B adenosine receptor; A3AR, A3 adenosine receptor; EOPE, 
early onset preeclampsia; LOPE, lope onset preeclampsia; HUVECs, human umbilical vein endothelial cells; n.m., not measured.  
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Table 2. Effect of the activation of adenosine receptors in human foetoplacental tissue in preeclampsia. 
 
Receptor 
subtype 
Type of 
preeclampsia  
Tissue or cells Agonist or 
antagonist 
Observed effect References 
      
A2AAR EOPE HUVECs CGS-21680 Increases cell proliferation, migration 
and VEGF protein release 
Escudero et al., 2013 
A2AAR LOPE Umbilical vein rings  ZM-241385 Restores preeclampsia-reduced insulin 
dilation 
Salsoso et al., 2015 
A2BAR LOPE Placenta villous explant  BAY60-6583 Induces FLT-1 gene expression and 
sFlt-1 secretion 
Iriyama et al., 2015 
A2BAR n.r. HTR-8/SVneo  NECA Increases phosphorylation of CREB at 
2% oxygen 
Darashchonak et al., 2014a 
A2BAR n.r. HUtMVEC/ 
HTR-8/SVneo coculture 
MRS 1754 Decreases trophoblast integration at 
2% oxygen 
Darashchonak et al., 2014a 
A3AR LOPE Placenta villous explant 2-CI-IB-MECA Induces MMP-2 and MMP-9 secretion 
at 3% oxygen 
Kim et al., 2008 
 
A2AAR, A2A adenosine receptor; A2BAR, A2B adenosine receptor; A3AR, A3 adenosine receptor; EOPE, early onset preeclampsia; 
LOPE, lope onset preeclampsia; HUVECs, human umbilical vein endothelial cells; HTR-8/SVneo, first trimester trophoblast cells; 
HUtMVEC, human uterine microvascular endothelial cells; CGS-21680, 2-[p-(2-carbonyl-ethyl)-phenylethylamino]-5′-N-
ethylcarboxamidoadenosine; ZM-241385, 4-(2-[7-amino-2-[2-furyl]-[1,2,4]triazolo[2,3-a]{1,3,5}triazin-5-yl-amino]ethyl)phenol; 
BAY60-6583, 2-[[6-Amino-3,5-dicyano-4-[4-(cyclopropylmethoxy)phenyl]-2-pyridinyl]thio]-acetamide; NECA, 5′-N-
ethylcarboxamidoadenosine; MRS 1754, N-(4-cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]-
acetamide; 2-CI-IB-MECA, 1-[2-chloro-6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-1-deoxy-N-methyl-ß-D-
ribofuranuronamide; VEGF, vascular endothelial growth factor; FLT-1, Fms related tyrosine kinase 1 gene; sFlt-1, soluble Fms-like 
tyrosine kinase-1; CREB, cAMP response element-binding protein; MMP-2, matrix metalloproteinase-2; MMP-9, matrix 
metalloproteinase-9; n.r., not reported.  
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Preeclampsia
Abnormal remodeling of 
uterine spiral arteries
Oxidative stress & 
inflammation
HIF-1a
NF-kB
Endothelial dysfunction
Endoplasmic reticulum 
stress & inflammation
UPR
Apoptosis
Reduced angiogenesis
sFlt1-14
sEng
VEGF
AT1 receptor activation
sFlt1
sEng
NADPH oxidase
O2
.–
Hypoxia
Ischemia
?
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Mother Foetoplacental tissue
Adenosine
Platelets activation
CD39 and CD73
ATP and AMP concentration
Hypoxia
ADA activity
Microthrombosis
Catecholamines release
IL-1β & TNF-α
CD73 (STB derived)
ATP and AMP concentration
Hypoxia/ischemia ?
ADA activity
hENT1
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Hypoxia ?
Reduced vasodilation
Increased vasoconstriction
NO
VEGF
Reduced angiogenesis
A2AAR
A2BAR
Preeclampsia
Adenosine
HIF-1α
HIF-2α
Outcome
Hypertension
Reduced vascular reactivity
Endothelial dysfunction
IUGR
hENT1
Adenosine
